Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

SVS quality initiative gathers data to improve vascular care
More than 7,000 physicians from a wide variety of healthcare specialties are already participating in the project.
Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban
When it came to all-cause mortality and ischemic stroke, however, the two popular DOACs were associated with comparable outcomes.
FDA warns that certain sizing catheters should not be used due to risk of breaking
These catheters from Cook Medical are associated with an increased risk of device fragmentation or vessel injury. Customers are urged to return them to the manufacturer.
FDA clears new AI model for pulmonary hypertension
The advanced algorithm, which previously received the FDA's breakthrough device designation, detects signs of pulmonary hypertension in standard 12-lead electrocardiograms.
Catheter-based treatment linked to major benefits for intermediate-risk PE
New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.

older patient with a doctor at their house

Learning more about AFib: 19 important topics for cardiologists, other heart specialists to investigate

New AFib recommendations from the American College of Cardiology and American Heart Association covered significant ground—but there is still much more to learn, experts explained.

New AFib guidelines include higher recommendations for catheter ablation, LAAO

Cardiologists, electrophysiologists, surgeons and patient representatives all worked together on the updated guidelines, which were published in both the Journal of the American College of Cardiology and Circulation.

Medtronic Penditure Left Atrial Appendage (LAA) Exclusion System

Medtronic debuts new FDA-cleared LAA exclusion device

Medtronic acquired the technology behind the new device back in August.

Bayer ends blood thinner trial early due to lack of efficacy

The Independent Data Monitoring Committee recommended Bayer stop the trial due to the drug's poor performance compared to apixaban.

FDA announces Class I recall of nearly 2,000 catheter kits

Medical facilities and distributors have been advised to immediately discontinue the use of these devices due to a significant labeling issue.

private equity corporatization business consolidation

Private equity-backed pharmaceutical company acquires stroke drug from Bayer

The drug, nimodipine, is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage.

Example of intravascular ultrasound (IVUS) shown as part of the multimodality imaging capability on the Fujifilm CVIS.

IVUS-guided PCI boosts 2-year survival, reduces need for bypass surgery

IVUS was especially effective when treating patients with a complex coronary anatomy, researchers found.

FDA grants breakthrough device designation to AI-powered, retinal imaging-based CVD assessments

CLAiR offers physicians another way to evaluate a patient’s cardiovascular health: non-invasive retinal images captured during routine eye exams.

Vascular & Endovascular

SVS quality initiative gathers data to improve vascular care

Post-TAVR bleeding in AFib patients much less common with apixaban than rivaroxaban

FDA warns that certain sizing catheters should not be used due to risk of breaking

FDA clears new AI model for pulmonary hypertension

Catheter-based treatment linked to major benefits for intermediate-risk PE